Determination of urinary albumin excretion in arterial hypertension;Determinación de la excreción urinaria de albúmina en la hipertensión arterial

Revista Clinica Espanola

Volumn 212, Issue 4, 2012, Pages 172-178

  De La Sierra, A ^a   Divison J A ^b   Garrido, P ^a   Barbon A ^c   Aristegui R ^c  

^a UNIVERSITY OF BARCELONA   (Spain)

^b Primary Care Center   (Spain)

^c AUTONOMOUS UNIVERSITY OF MADRID   (Spain)

Author keywords

Hypertension; Microalbuminuria; Target organ damage; Urinary albumin excretion

Indexed keywords

ALBUMIN; CREATININE;

AGE; AGED; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL EVALUATION; CREATININE CLEARANCE; DIABETES MELLITUS; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MICROALBUMINURIA; OBESITY; PREVALENCE; PRIMARY MEDICAL CARE; PROTEIN DETERMINATION; PROTEIN URINE LEVEL; URINALYSIS; URINARY EXCRETION; VALIDATION PROCESS;

ADULT; AGED; ALBUMINURIA; CROSS-SECTIONAL STUDIES; FEMALE; GUIDELINE ADHERENCE; HUMANS; HYPERTENSION; LOGISTIC MODELS; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; PRIMARY HEALTH CARE; SPAIN;

EID: 84859475986     PISSN: 00142565     EISSN: 15781860     Source Type: Journal    
DOI: 10.1016/j.rce.2011.09.010     Document Type: Article

References (25)

1. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 guidelines for the management of arterial hypertension. J Hypertens. 2007;25:1105-87.
2. de la Sierra A, Gorostidi M, Marín R, Redón J, Banegas JR, Armario P, et al. Evaluación y tratamiento de la hipertensión arterial en España, 2008. Med Clin (Barc). 2008;131:104-16.
3. Brosius FC, Hostetter TH, Kelepouris E, Mitsnefes MM, Moe SM, Moore MA, et al. Detection of chronic kidney disease in patients with or at increased risk of cardiovascular disease. A science advisory form the American Heart Association Kidney and Cardiovascular Disease Council; the Councils for High Blood Pressure Research, Cardiovascular Disease in the Young, and Epidemiology and Prevention; and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation. 2006;114:1083-7.
4. Executive Summary Standards of medical care in diabetes-2011. Diabetes Care. 2011;34:S4-10.
5. Viberti GC, Hill RD, Jarrett RJ, Argyropoulos A, Mahmud U, Keen H. Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet. 1987;1:1430-2.
6. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med. 1984;310:356-60. (Pubitemid 14179541)
7. Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Eng J Med. 2001;345:870-8.
8. Brenner BM, Cooper ME, De Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Eng J Med. 2001;345:861-9.
9. Pedrinelli R, Dell'omo G, Catapano G, Giampietro O, Carmassi F, Matteucci E, et al. Microalbuminuria and endothelial dysfunction in essential hypertension. Lancet. 1994;344:14-8. (Pubitemid 24199418)
10. Jensen JS, Feldt-Rasmussen B, Strandgaard S, Schroll M, Borch-Johnsen K. Arterial hypertension, microalbuminuria, and risk of ischemic heart disease. Hypertension. 2000;35: 898-903. (Pubitemid 30303947)
11. Romundstad S, Holmen J, Hallan H, Kvenild K, Ellekjaer H. Microalbuminuria and all-cause mortality in treated hypertensive individuals. Does sex matter? The Nord-Trøndelag Health Study (HUNT), Norway. Circulation. 2003;108:2783-9.
12. Wachtell K, Ibsen H, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE, et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med. 2003;139:901-6.
13. Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE, et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension. 2005;45:198-202. (Pubitemid 40179960)
14. Ninomiya T, Perkovic V, de Galán BE, Zoungas S, Pillai A, Jardine M, et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol. 2009;20:1813-21.
15. de la Sierra A, Egocheaga MI, Aguilera MT. Prevalencia y características clínicas de la microalbuminuria en la población española con hipertensión arterial. Med Clin (Barc). 2008;130:201-5. (Pubitemid 351520658)
16. Waeber B, de la Sierra A, Ruilope LM. Target organ damage: how to detect and how to treat it? J Hypertens. 2009;27 Suppl 3:S13-8.
17. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens. 2009;27:2121-58.
18. de la Sierra A. Prevención de la progresión y regresión de la lesión orgánica. Estrategias de futuro. Rev Clin Esp. 2011;211 Supl 1:S8-14.
19. Galcerán JM. Nefroprotección y riesgo vascular: prevención del daño renal en la hipertensión arterial. Rev Clin Esp. 2011;211 Supl 1:S15-20.
20. Porres LD, Solans MR, Oña MF, Morilla L, Isarn RM, Milian ES, et al. Control integral de los factores de riesgo vascular en los pacientes con diabetes tipo 2 de las regiones de Pallars Jussà y Sobirà (área de influencia del hospital Pallars-Lleida). Rev Clin Esp. 2010;210:332-7.
21. Calderón A, Escobar C, Barrios V. ¿Debemos modificar nuestra conducta terapéutica como consecuencia de la revisión de 2009 de la guía para el manejo de la hipertensión arterial de la ESH/ESC? Rev Clin Esp. 2010;210:511-6.
22. Díez J. ¿Qué ha cambiado en el manejo actual de la hipertensión arterial desde el punto de vista renal? Rev Clin Esp. 2010;210 Supl 1:S12-7.
23. de la Sierra A, Segura J, Banegas JR, Gorostidi M, de la Cruz JJ, Armario P, et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension. 2011;57:898-902.
24. Oliveras A, Armario P, Martell-Claros N, Ruilope LM, De la Sierra A. Urinary albumin excretion is associated with nocturnal systolic blood pressure in resistant hypertensives. Hypertension. 2011;57:556-60.
25. Oliveras A, Armario P, Hernández-del-Rey R, Arroyo J, Poch E, Larrousse M, et al. Urinary albumin excretion is associated with true resistant hypertension. J Human Hypertens. 2010;24:27-33.